Figure S6. Effect of AZD9291 in NCI-H3255 and PC-9VanR xenograft models. 5mg/kg/day of AZD9291 induces significant tumour shrinkage in A, NCI-H3255 (L858R) n=12 and B, PC-9VanR (ex19del/T790M) n=12 in controls and n=8 in treated.
Figure S6. AZD9291 has no significant effect on animal body weight.
No significant body weight changes were observed during long term tumour growth inhibition studies with AZD9291 in either C, PC-9 or D, NCI-H1975 subcutaneous xenograft models.
Figure S6E. AZD9291 exhibits moderate efficacy in an A431 wild-type EGFR xenograft model. Tumor volume measurements (mean ± s.e.m) in A431 subcutaneous xenograft model in response to 5 mg/kg/day of AZD9291 compared to 7.5 mg/kg/day afatinib following 14 days of daily treatment (n = number of mice per treatment group shown).